About Eos Biosciences, Inc
Eos Biosciences Inc. is a privately-held, Los Angeles-based, Biotargeted Nanomedicines company founded in 2013. The Company has secured an exclusive world-wide license to a novel drug-targeting platform technology developed at Cedars-Sinai Medical Center (Los Angeles). The technology is based on generating self-assembling, non-liposomal, biotargeted nanoparticles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell by mediating active endosomal escape. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload. The Eosomes efficiently entrap and package small molecule therapeutics as well as many forms of oligonulceotide therapeutics including single and double strand DNA oligonucleotides, siRNA, miRNA, mRNA and plasmid DNA.
Eos Biosciences has a pipeline of proprietary products for oncology specifically targeting a wide variety of metastatic, drug resistant, solid tumors. Eos anticipates advancing the first proof of principle product into phase 1 clinical study in 2017.
CEO & Co-Founder, Zapnito
Sales Account Executive, Springer Nature